Objective: The objectives of the study were to determine the impact of nocebo effects on adverse events (AEs) in drug trials in fibromyalgia syndrome (FMS) and painful diabetic peripheral neuropathy (DPN).
V alid information about adverse events (AEs) is crucial for determining the benefit-risk ratio for a given medication. Clinical decisions on drug use should depend not only on drug efficacy but also depend on drug safety and tolerability. 1 Safety implies AEs with organ damage such as hepatic toxicity assessed by objective tests. Tolerability involves AEs that are reported by the patient and are considered to be irritating such as dizziness and nausea but not associated with organ damage.
2 Irritating (subjective) AEs influence patient behavior in terms of medication adherence and drug discontinuation. 3 Subjective AEs are examined in double-blind, randomized, controlled trials (RCTs) by comparing the symptoms reported by patients in "true" drug-treated groups with those reported by patients in placebo groups. The assumption is that symptoms found in true drug-treated groups result from a combination of specific pharmacological effects and nonspecific effects that also occur in the placebo groups. These nonspecific negative effects of placebos are termed the "nocebo effect." 1, 4 The nocebo effect is explained by patient-related psychological factors such as negative expectations, conditioning of adverse reactions on medication, and personality traits (eg, somatization, anxiety) and contextual factors such as negative suggestions of the physician. 4, 5 Moreover, the ascertainment strategy of AEs influences the tolerability profile of drugs. 1, 2 To our knowledge, the question to which amount AEs in drug trials in pain medicine are determined by nocebo effects had not been studied. Only a few studies addressed the magnitude and putative predictors of nocebo effects in drug trials of migraine. In studies on acute migraine treatment in adults, a mean of about 23% patients reported at least 1 AE after placebo. The rate of AEs in placebo groups was higher in studies performed in North America than in Europe. 6 In migraine trials, the type of AEs in placebo arms depended on the AEs of true medication against which the placebo was compared. No associations between side effects in placebo groups and some studyrelated (sample size, publication year) and patient-related (sex, age, weight, race, type of migraine, migraine frequency) characteristics were found. 7, 8 Migraine patients under triptans reported more AEs in a prompted questionnaire compared with an unprompted questionnaire. 2 The impact of nocebo effects on AEs and its patientrelated and study-related predictors in drug trials of other chronic pain conditions such as fibromyalgia syndrome (FMS) and painful peripheral diabetic neuropathy (PDN) had not been studied. The purposes of this review therefore were:
To determine to which amount nocebo effects accounted for AEs in the true drug groups
To test for patient-related and study-related characteristics associated with nocebo effects
In RCTs of drug therapy in patients with FMS and painful PDN.
METHODS

Hypotheses
Patient Characteristics
Due to the limited findings in the literature, we had no a priori hypotheses on the impact of age, sex, and race on nocebo effects. We hypothesized that nocebo drop out rates will be higher in FMS than in painful diabetic peripheral neuropathy (DPN). Somatization had been assumed to be associated with nocebo effects 4 and had been described to be a main feature of FMS. 9 
Study-related Characteristics
We had no a priori hypothesis on the impact of year of study initiation on nocebo effects because of divergent results on nocebo effects in migraine 7 and multiple sclerosis 3 trials. We hypothesized that treatment duration would be associated with nocebo effects as shown in multiple sclerosis trials. 3 We expected higher rate of nocebo effects in studies with centrally acting agents (antidepressants, anticovulsants) than in studies with other medication. 10 We assumed that the incidence of nocebo effects would be higher in trials with structured assessment of side effects than in studies with spontaneously reported or observed side effects as shown in studies with statins, antidepressants, and migraine.
1,2,11
Protocol
The review was performed according to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses statement 12 and the recommendations of the Cochrane Collaboration. 13 Methods of analysis and inclusion criteria were specified in advance (review protocol available on request).
Data Sources and Searches
Painful DPN
We used the search strategy of the guideline of the National Institute for Clinical Excellence on pharmacological management of neuropathic pain 14 for MEDLINE. The search strategy was adapted to SCOPUS, the Cochrane Central Register of Controlled trials (CENTRAL), websites of the U.S. National Institutes of Health (www.clinical trials.gov) and the Pharmaceutical Research and Manufacturers of America (www.clinicalstudyresults.org). The search was conducted until December 31, 2010.
FMS
We expanded our searches used for the German interdisciplinary guideline on the management of FMS 15 in the electronic bibliography databases, detailed above, until December 31, 2010. Details of the search strategy had been outlined in a recent publication. 16 Both search strategies are presented in Supplemental Table 1 (Supplemental Digital Content 1, http://links.lww.com/CJP/A28).
For both conditions, we reviewed the reference lists of included studies. Two authors independently screened the titles and abstracts of potentially eligible studies identified by the search strategy detailed above. The full text studies were then examined independently by 2 authors to determine whether they met the inclusion criteria. Discrepancies were rechecked and resolved by consensus.
Selection
Types of Studies
Double-blind RCTs with a parallel design were included. Studies without randomization, single blind, and single session studies were excluded. Studies with an enriched enrollment and consecutive randomized withdrawal design were excluded because of the potential effects of the study design on placebo and thus potentially on nocebo effects. 17 Crossover studies were excluded from analysis. If placebo is given as the first treatment, one is measuring the effects of suggestion only, whereas if placebo is given as a second treatment, one is measuring the effects of both suggestion and conditioning. 7 
Types of Participants
Patients with painful PDN and FMS, diagnosed by defined criteria, were included. We excluded studies in which PDN was mixed with other neuropathic pain syndromes if no separate data for DPN were reported.
Types of Interventions
RCTs comparing any type of pharmacological medication with pharmacological placebo were included. Studies with nonpharmacological placebos and with pseudoplacebos (pharmacodynamically active substance without evidence for effectiveness in the disease of interest) were excluded. Studies that combined pharmacological placebo with any other defined treatment, whose effects on pain were tested for, were excluded. Study duration should be at least 2 weeks.
Types of Outcomes Measures
The outcome measures for nocebo effects were the number of patients with at least 1 AE of any type (light, moderate, and severe) and the drop out rate due to AEs in placebo and true drug group for each study. 3 For inclusion, studies should report at least 1 of these 2 outcomes.
Data Abstraction
A structured coding plan was developed before the analysis. Two investigators independently extracted the data of all studies detailed below using standard extraction forms. Discrepancies were rechecked and consensus achieved by discussion. If needed a third investigator reviewed the data to reach a consensus. The coding plan included the following items.
Outcomes
We examined the incidence of the number of patients with at least 1 AE and drop out rates (total and due to AEs) in placebo and true drug groups of each trial. For trials with more than 1 dosage group of true drug, we chose the group with the highest dosage for comparison.
Patient Characteristics
Mean age, sex (percentage of females), and race (percentage of Caucasians) of the study participants were extracted.
Study Characteristics
The following variables were collected: year of initiation (if unavailable, estimated as 3 years before publication) 18 and publication of the study; sponsoring by pharmaceutical company (if support was not mentioned, we checked the acknowledgement sections and the affiliations of the authors for study support by pharmaceutical companies); continent in which the study took place (Europe, North America, Asia, mixed continent samples); number of study sites (if not reported, we chose the number of clinical institutions of the author list); type of active medication (antidepressants, anticonvulsants, other); application of medication (oral, topical, parenteral); approval by the Food and Drug Administration for FMS, respectively, painful DPN; total sample sizes in true drug and placebo group; treatment duration in weeks; publication status (peer reviewed journal versus only available in database); assessment strategy of AEs (structured assessment, observations, spontaneous reports, combination of assessment methods).
Validity Assessment
Two investigators independently collected the reported quality assessment of reports of randomized clinical trials in terms of Jadad scores, considering the description and sequence of randomization, the double-blind procedure, the appropriateness of randomization and double-blinding procedures, and the description of withdrawals and dropouts (range, 0 to 5). 19 Discrepancies were rechecked and resolved by consensus and if needed by a third investigator. Interrater reliability for study characteristics and validity characteristics were computed.
Dealing with Missing Data
Where details of study outcomes were missing, attempts were made to obtain these data through contacting 74 trial authors. Additional data were provided by 12 authors. We did not ask for not reported details of study design (eg, method of randomization, identity of active drug and placebo, type of AE assessment) because we were unable to receive these details of conducted before 2000 in previous systematic reviews on antidepressants in FMS. 20 
Risk of Bias in Individual Studies
The risk of bias in individual studies was assessed by summarizing the study quality in the Jadad score. 19 
Statistical Analysis
Descriptive statistics were used to characterize the features of the included trials. Nonparametrical tests were used for the comparison of continuous variables and w 2 tests for the comparison of categorical variables. Correlations between continuous variables were calculated by Pearson correlation coefficients. A 2-sided P value of r0.05 was considered significant.
Pooled estimates of event rates of AEs in placebo and true drug groups and risk ratios for the combined studies were calculated using a random effects model. 20 Metaregression analyses were performed to determine whether linear relations exist between patient-related (mean age, percentage of women and of Caucasians of study participants) and study-related (incremental year of study initiation, study quality) characteristics (independent variables) and the logit rate of AEs in placebo groups (dependent variable). Metaregression used the random effects model. Tau square variance was calculated by the method of maximum likelihood.
To test the potential impact of categorical variables (types of assessment of AEs), a test of interaction with a predetermined 2-tailed a of 0.05 was used. 21 The I 2 statistics was used to estimate the percentage of total variation across studies because of heterogeneity, rather than by chance (ie, the percentage of variability of associations across studies that is not due to chance or random error, but rather due to real differences in study patients, design, or outcome definitions). I 2 values of <25% represent low, 25% to 50% moderate, and Z50% substantial heterogeneity. 13 Publication bias was assessed first by drawing a funnel of standard error of the relative risk of drop out due to AEs in true drug versus placebo group. In addition, the Egger intercept test 22 and the Begg rank correlation test 23 were performed at the significance level P<0.05. We a priori decided to metaregress the relative risks of the pooled estimates of AEs in placebo group with the Jadad score. The statistical calculations were performed using SPPS version 17.0 (SPSS, Inc., Chicago, 2009) and Comprehensive Metaanalysis version 2.0 (Biostat, Englewood, 2010).
RESULTS
Search of Literature
One thousand two hundred fifty-one in FMS and 1034 studies in painful DPN different studies fulfilled the first level of inclusion criteria. After excluding studies based on information presented in study abstracts, 86 complete study reports were considered in more detail in FMS and 84 in 
Study Characteristics
Study Design and Patient Characteristics
A total of 5027 patients in placebo and 5065 patients in true drug group of FMS trials were included into analysis. A total 5086 patients in placebo and 5296 patients in true drug groups of DPN trials were included into analysis. There were no significant differences in the year of study initiation, publication status, approval status by the Food and Drug Administration for FMS painful DPN, respectively, types of application of medication, sample size in true drug group and baseline pain scores of patients on placebo between the 2 diseases. Trials with painful DPN significantly included more study sites and countries, were more frequently conducted in mixed continent samples, used more frequently anticonvulsants and less antidepressants, had greater sample sizes in placebo groups and included more older, male and non-Caucasians patients than FMS trials ( Table 1 ). The characteristics of each study for which data were extracted are presented in Tables 2 and 3 .
Assessment Strategy of AEs
Twenty-two of 58 (37.9%) of FMS-trials reported some details of the assessment strategy. In 10 studies, AEs were assessed by a combination of spontaneous reports and exploration and observation. Three of these studies indicated that the observation/exploration was performed by the investigator. Five studies relied on spontaneous reports, 6 on exploration (of which 2 reported the use of a checklist) and 1 on a structured interview.
Fourteen of 62 (22.6%) of the DPN trials reported some details of the assessment strategy. In 2 studies, AEs were assessed by a combination of spontaneous reports and exploration and observation. Nine studies relied on spontaneous reports, 2 on exploration, and one on a structured interview (Tables 2 and 3 ).
Reported Study Quality
The means of the Jadad score did not differ between FMS and painful DPN trials (Table 1) .
Validity Assessments
The interrater reliability for the assessments of the study sample and outcome characteristics ranged from 0.86 to 0.92 and was for study quality r = 0.94.
Nocebo Effects
FMS Trials
The pooled estimate of the event of rate of patients with at least 1 AE in placebo groups was 59.9 (95% CI: 53.8-65.8) and in true drug groups was 73.3 (95% CI: 66.0-79.6). There was a high linear correlation between the event rates in placebo and active drug groups with r = 0.83 (P<0.001). Nocebo effects accounted for 81.7% of the event rate of patients with at least 1 AE in true drugs.
The pooled estimate of the event rate of drop outs because of AEs accounting for total drop rate was 52.2 (95% CI: 46.3-57.9). The pooled estimate of the event rate of drop out due to AEs in placebo groups was 9.6 (95% CI: 8.6-10.7) and in true drug groups was 16.3 (95% CI: 14.1-31.2). There was a moderate linear correlation between the event rates in placebo and active drug groups with r = 0.74 (P<0.001). Nocebo effects accounted for 58.9% of the event rate of drop out in true drugs. The forest plots of the event rates patients with at least one AE and dropping out due to AEs are presented in Supplemental Figure 3 (Supplemental Digital Content 4, http://links.lww.com/ CJP/A31).
DPN Trials
The pooled estimate of the event rate of patients with at least 1 AE in placebo groups was 46.2 (95% CI: 36.5-56.1) and in true drug groups was 63.5 (95% CI: 53.6-72.4). There was a high linear correlation between the event rates in placebo and active drug groups with r = 0.91 (P<0.001). Nocebo effects accounted for 72.8% of the event rate of patients with at least 1 AE in true drugs.
The pooled estimate of the event rate drop out because of AEs accounting for total drop rate was 54.7 (95% CI: 49.4-59.9). The pooled estimate of the event rate drop out rate due to AEs in placebo groups was 5.8 (95% CI: 5.1-6.6) and in true drug groups was 13.2 (95% CI: 10.7-16.2). There was a moderate linear correlation between the event rates in placebo and active drug groups due to AEs with r = 0.62 (P<0.001). Nocebo effects accounted for 43.9% of the event rate drop out due to AEs in true drug groups. The forest plots of the event rates patients with at least 1 AE and dropping out due to AEs are presented in Supplemental 
Subgroup Analyses
Due to the poor quantity and quality of the reports on assessment strategies of AEs, we post hoc decided not to perform subgroup analyses of the different assessment strategies. The event rate of patients with at least 1 AE and dropping out due to AEs were higher in FMS than in DPN trials (P interaction 0.02 and <0.001).
Metaregression Analyses
The regression coefficients for mean age and incremental year of study initiation on the logit of the event rates of patients with at least 1 AE were significant, indicating a strong linear correlation both in FMS and DPN trials. The regression coefficients of mean age, mean percentage of women, incremental year of study initiation, and study duration on the logit of event rates of patients dropping out to AEs were significant indicating a strong linear correlation both in FMS and DPN trials ( Table 4) .
Risks of Bias
Heterogeneity
I
2 of the pooled estimate of the event rate of patients with at least 1 AE was 60.5% and of drop out due to AE was 3.0% in the placebo groups of FMS trials. I 2 of the pooled estimate of the event rate of number of patients with at least 1 AE was 55.9% and of drop out due to AE was 0% in the placebo groups of DPN trials.
The relative risk of the event rate of patients with at least 1 AE comparing true drug versus placebo in FMS trials was 1.2 (95% CI: 1.1-1.3; I 2 = 4.4%) and in painful DPN trials was 1.3 (95% CI: 1.2-1.5, I 2 = 31.3%). The relative risk of the event rate of drop out due to AEs comparing true drug versus placebo in FMS trials was 2.1 (95% CI: 1.8-2.4; I 2 = 0%) and in painful DPN trials was 2.8 (95% CI: 2.3-3.3, I 2 = 0%).
Reported Study Quality
The Jadad score was not significantly associated with the logit pooled estimate of the event rate of at least 1 AE ( = 0.51, P = 0.20, df = 33), but with the logit pooled estimate of the event rate of drop out due to AE in placebo groups of FMS trials ( = À 2.16, P = 0<0.001, df = 58). The Jadad score was not significantly associated with the logit pooled estimate of the event rate of at least 1 AE ( = À0.98, P = 0.09, df = 28), but with logit pooled estimate of the event rate drop out due to AE in placebo groups of painful DPN trials ( = À3.02, P = 0<0.001, df = 59).
Publication Bias
Visual inspection of funnel plots was not indicative for publication bias (details not shown). The Kendall tau of the Begg rank correlation test of the relative risk drop out due to AEs true drug compared with placebo was not significant in FMS (tau = À 0.13, P 2-tailed = 0.14) and painful DPN trials (tau = À0.02, P =0.85). The Egger intercept of the relative risk drop out due to AEs true drug compared with placebo was not significant in FMS (intercept = 0.12, 
DISCUSSION
Summary of Main Results
Nocebo effects accounted for 82% of the event rate of patients with at least 1 AE in FMS and for 73% painful DPN trials. Nocebo effects accounted for 72% of the drop out rate to AE in FMS and for 44% painful DPN trials. The magnitude of nocebo effects was associated in both diseases with higher incremental year of study initiation and with longer duration of the study.
Agreement With Other Studies on Nocebo Drop Out Rates in Clinical Drug Trials
Incidence of Nocebo Effects
The pooled event rate of patients with at least 1 AE in placebo groups in FMS and in painful DPN was higher than the one of migraine trials with 23%. 6 The pooled event rates of drop out due to AEs in placebo groups in FMS and painful DPN were higher than the ones reported in multiple sclerosis with 2.1% in disease modifying and 2.3% in symptomatic treatment trials. 3 Rief et al 1 found a great variability of drop out rates (4% to 20%) in placebo groups in statin therapies of randomized controlled trials in atherosclerosis diseases. 1 The migraine studies did not analyze drop out rates due to AEs in placebo groups. 6, 7 Trial and Patient Characteristics Associated With Nocebo Effects Nocebo drop out rates exhibited an association with the year of study publication in multiple sclerosis 3 trials likewise in our study. On the basis of the expectancy theory of nocebo, 5 we hypothesize that the number of patients with former negative experience with drugs and lower tolerance to adverse effects increased over the years. Information regarding trial medications made increasingly available by the media and other sources including the internet may have contributed to patients discontinuing trial medications more easily today than 20 years ago. The decline in tolerance to unspecific symptoms may also reflect the greater availability of therapeutic options or even the increasing possibilities for participating in clinical trials seen in the last 20 years. 3 In accordance with our findings, side effects in placebo groups were not associated with race in migraine medication, 6, 7 statins, 2 and oral drug challenge trials. 24 In contrast to these studies, 2, 6, 7, 24 we found a positive association of female sex with drop out due to AEs. Our results confirm pharmacovigilance observations that medication side effects occur more frequently in older than in middle-aged patients. 25 We speculate that the higher nocebo drop out rates in FMS are due to higher levels of anxiety and somatization compared with painful DPN patients although we do not know direct comparisons of these psychological variables in both diseases.
Limitations
Methods
The inherent difficulty in attributing non-specific symptoms to be drug-related has to be recognized as a source of clinical heterogeneity between the trials. The decision to register a drug-related AE might depend if the exploration was performed by study nurse or medical doctor, if leading or nonleading questions and prompted or unprompted questionnaires were used. These details of assessment strategy of AE were not reported by nearly half of the studies and insufficiently outlined by the reporting studies. Moreover, the types of assessment differed in the reporting studies. As a result of the lacking or insufficient data, we were unable to test for the impact of the assessment strategy on the incidence of nocebo effects. Therefore, the pooled estimates of the nocebo effects must be handled with extreme caution. However, heterogeneity of the drop out rates due to AEs in placebo group and the relative risks of the event rates of patients with at least 1 AE and dropping out due to AEs were low. Therefore, pooling of estimates of nocebo effects and metaregression analyses were justified from a methodological point of view. The high amount to which nocebo effects accounted for drop out due to AEs does likely not depend on the assessment strategy of AEs of the studies analyzed.
Further major limitations of systematic reviews are publication bias, quality of the included studies, and insufficient data. We did not find indicators for publication bias. We found that the magnitude of nocebo effects was associated with higher reported study quality. We had to exclude some studies because of insufficient data from analysis. These studies were mainly studies with small sample sizes that had been conducted before 2000. Their results-if available-would probably not have substantially changed the results. The total sample size and the number of studies included in our meta-analysis were sufficiently high for the outcome variable. Some of the studies included did not report in detail the characteristics of their study samples, especially demographic characteristics of the patients such as race limiting the validity of the results of the metaregression analysis. There is an ecological bias in the metaregression analyses performed, as the analysis was conducted at the study level and did not include the underlying patient-level variation. 26 
Variables Analyzed
To reduce errors to due multiple testing, we did not assess other potential moderators of nocebo effects such as type and frequency of drug application. Meta-analyses are limited in providing understanding of factors that contribute to nocebo effects because they do not systematically vary factors that affect its magnitude. We could not assess putative patient-related predictors of nocebo response such as anxiety and somatization. 1 Verbal suggestions and behaviors manifested by healthcare providers are likely to vary greatly across research contexts and may consequently generate considerable variability in nocebo effects. 27 
CONCLUSIONS
Reliable data on the tolerability and safety of a drug are necessary for clinical decision making. Regulatory agencies should define standards of the assessment of AEs in drug trials applying for approval. A recent study suggested to use a combination of sophisticated approaches for expected side effects, systematic screening for general side effects, and open question methods for spontaneous reports. 10 Reviewers and editors of peer-reviewed journals should demand a detailed report of the assessment strategy of AEs.
Awareness of nocebo effects is a prerequisite for enabling clinical investigators and practitioners to better recognize AEs. Better elucidation of patient characteristics such as anxiety, somatization and previous negative experiences with drugs and of contextual factors such as content and style of communication potential AEs would allow the development of strategies to prevent or minimize nocebo effects in both clinical trials and clinical practice. 4 
